Stockscreener 앱 받기
16.46
5.18%
0.81
시간 외 거래:
16.61
0.15
+0.91%
전일 마감가:
$15.65
열려 있는:
$16.2
하루 거래량:
3.68M
Relative Volume:
1.37
시가총액:
$1.88B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-8.1485
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+0.67%
1개월 성능:
+25.27%
6개월 성능:
+81.28%
1년 성능:
+23.57%
1일 변동 폭
$16.11
$17.16
1주일 범위
$15.12
$17.16
52주 변동 폭
$6.78
$17.70
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
16.46 | 1.98B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
270.50 | 44.75B | 2.97B | 809.93M | 1.33B | 4.8743 |
|
TEM
Tempus Ai Inc
|
65.69 | 12.29B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
100.73 | 8.92B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
46.42 | 9.04B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
34.79 | 6.66B | 906.14M | -52.62M | 89.62M | -0.3621 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
Spatial Biology Market Analysis and Forecast, 2025-2035: - GlobeNewswire
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
How 10x Genomics Inc. (1KJ) stock trades pre earnings2025 Support & Resistance & Reliable Breakout Forecasts - newser.com
Total liabilities & shareholders' equities of 10x Genomics Inc Class A – HAM:1KJ - TradingView
Is 10x Genomics Inc. stock a buy before product launchesJuly 2025 Closing Moves & Safe Entry Zone Tips - newser.com
10x Genomics (Nasdaq: TXG) Xenium Powers ASTRA Atlas of 2,000 Asia-Pacific Tumor Samples - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.47% to 16.66 - Nasdaq
10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch - MSN
TXG (10x Genomics) Inventory-to-Revenue : 0.44 (As of Sep. 2025) - GuruFocus
10x Genomics Announces Chief Legal Officer Retirement - MSN
10x Genomics GC Who Led Rule Of Law Effort To Retire In '26 - Law360
There's Reason For Concern Over 10x Genomics, Inc.'s (NASDAQ:TXG) Massive 42% Price Jump - simplywall.st
10x Genomics, Inc. Announces Executive Changes, Effective January 1, 2026 - MarketScreener
10X Genomics Stock Soars 17.31%, Hits Intraday High of $15.26 - Markets Mojo
10x Genomics Inc Class A Earnings and Revenue – HAM:1KJ - TradingView
How 10x Genomics Inc. (1KJ) stock valuation compares with sectorChart Signals & Safe Entry Point Alerts - newser.com
Why 10x Genomics Inc. (1KJ) stock attracts wealthy investorsSell Signal & Verified Stock Trade Ideas - newser.com
10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025 - Eastern Progress
10x Genomics, Inc. (TXG) Stock Price Quote Today & Current Price Chart - Capital.com
10x Genomics (TXG): Assessing Valuation After Strong Earnings, Upbeat Forecast and New Product Launch - Yahoo Finance
Piper Sandler Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
10x Genomics to Participate in the Wolfe Research Healthcare Con - GuruFocus
10x Genomics (TXG) Soars to New Record High on Lower Net Loss, Revenue Beat - Insider Monkey
Why 10x Genomics (TXG) Stock Is Trading Up Today - Yahoo Finance
Is 10x Genomics Inc. stock ready for a breakoutWeekly Market Summary & AI Enhanced Trading Signals - newser.com
Can a trend reversal in 10x Genomics Inc. lead to recovery2025 Volume Leaders & Real-Time Volume Analysis - newser.com
10x Genomics stock hits 52-week high at 17.26 USD - Investing.com
10x Genomics, Inc.'s (NASDAQ:TXG) 33% Price Boost Is Out Of Tune With Revenues - 富途牛牛
Research Alert: CFRA Keeps Hold Rating On Shares Of 10x Genomics, Inc. - 富途牛牛
10X Genomics Tops Q3 Estimates And Cuts Losses - Finimize
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Eledon Pharmaceuticals (ELDN) and AMN Healthcare Services (AMN) - The Globe and Mail
10x Genomics (TXG): How Fresh Results and New Guidance Are Shaping Its Valuation - simplywall.st
10x Genomics, Inc. (NASDAQ:TXG) Q3 2025 Earnings Call Transcript - Insider Monkey
Canaccord Genuity Maintains 10x Genomics (TXG) Buy Recommendation - Nasdaq
JP Morgan Maintains 10x Genomics (TXG) Neutral Recommendation - Nasdaq
TXG: Canaccord Genuity Raises Price Target for 10x Genomics to $19 | TXG Stock News - GuruFocus
GUIDANCE: (TXG) 10x Genomics, Inc. Expects Q4 Revenue Range $154.0M$158.0M - 富途牛牛
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics: Q3 Earnings Snapshot - CT Insider
Is 10x Genomics Inc. stock supported by strong fundamentalsPortfolio Risk Report & Safe Entry Trade Signal Reports - newser.com
10x Genomics Inc (TXG) Q3 2025 Earnings Call Highlights: Navigat - GuruFocus
Transcript : 10x Genomics, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Is 10x Genomics Inc. (1KJ) stock undervalued historicallyQuarterly Portfolio Report & Proven Capital Preservation Methods - newser.com
10x Genomics (TXG) Reports Q3 Loss, Beats Revenue Estimates - sharewise.com
Compared to Estimates, 10x Genomics (TXG) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
[10-Q] 10x Genomics, Inc. Quarterly Earnings Report | TXG SEC FilingForm 10-Q - Stock Titan
10X Genomics Q3 revenue beats expectations, net loss narrows - MarketScreener
10x Genomics Inc (TXG) Q3 2025 Earnings: EPS of -$0.22 Beats Est - GuruFocus
10x Genomics’s (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1% - Yahoo Finance
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.62%
0.03%
자본화:
|
볼륨(24시간):